Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Income from Continuing Operations (2016 - 2021)

Historic Income from Continuing Operations for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $22.5 million.

  • Neurocrine Biosciences' Income from Continuing Operations rose 13906.25% to $22.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $39.3 million, marking a year-over-year decrease of 5792.83%. This contributed to the annual value of $37.0 million for FY2019, which is 7532.09% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Income from Continuing Operations of $22.5 million as of Q3 2021, which was up 13906.25% from $42.3 million recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' Income from Continuing Operations ranged from a high of $79.6 million in Q2 2020 and a low of -$102.1 million during Q1 2019
  • In the last 5 years, Neurocrine Biosciences' Income from Continuing Operations had a median value of $20.7 million in 2018 and averaged $3.9 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 29366.3% in 2017, then skyrocketed by 96757.99% in 2019.
  • Neurocrine Biosciences' Income from Continuing Operations (Quarter) stood at $6.9 million in 2017, then skyrocketed by 172.82% to $18.8 million in 2018, then skyrocketed by 80.84% to $34.0 million in 2019, then tumbled by 269.35% to -$57.6 million in 2020, then surged by 139.06% to $22.5 million in 2021.
  • Its Income from Continuing Operations stands at $22.5 million for Q3 2021, versus $42.3 million for Q2 2021 and $32.1 million for Q1 2021.